Changing the way that inflammatory diseases are treated
Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh. Our academic founders are developing an inhibitor of E3 ligase Fbxo3, which is implicated in the pathogenesis of inflammatory conditions such as inflammatory bowel disease (including ulcerative colitis and Crohn’s Disease), bronchiolitis obliterans syndrome, chronic obstructive pulmonary disease, acute lung injury, and rheumatoid arthritis. The lead compound has successfully completed IND-enabling studies. The company expects to file an IND application in late 2018.